查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813272

DNA編碼庫市場預測至2032年：材質、工作流程、技術、分銷管道、應用、最終用戶和地區進行的全球分析

DNA Encoded Library Market Forecasts to 2032 - Global Analysis By Material (DNA Oligonucleotides, Chemical Linkers and Synthetic Building Blocks), Workflow, Technology, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球 DNA 編碼庫市場規模預計在 2025 年達到 35 億美元，到 2032 年將達到 67 億美元，預測期內的複合年成長率為 9.8%。

DNA編碼化合物庫是由化學連接到獨特DNA序列的小分子組成的集合，這些DNA序列充當條碼，能夠快速識別具有生物活性的化合物。它們用於藥物研發，能夠針對目標蛋白對數百萬至數十億種化合物進行高通量篩檢。 DNA標籤能夠有效率地篩選、擴增和序列測定潛在的候選藥物。這項技術融合了化學和分子生物學，簡化了早期藥物研究，並顯著加快了有前景的先導化合物的鑑定。

據世界衛生組織 (WHO) 稱，隨著製藥公司尋求多樣化其產品線並發現新化合物以滿足未滿足的醫療需求，特別是在癌症、神經系統疾病和罕見遺傳疾病方面（DECL 在這些方面具有特別的前景），越來越多的藥物研發資源被分配給 DECL 等創新藥物研發技術。

加大對醫藥研發的投入

DNA編碼化合物庫市場的發展得益於不斷增加的藥物研發投入，旨在加速藥物發現。製藥公司和研究機構正在投入大量資金用於先進的篩檢技術，以有效識別候選藥物。 DEL平台能夠快速測試數十億種化合物，從而降低臨床前階段的成本和時間。在慢性病發病率上升和精準醫療需求的推動下，藥物研發的擴張持續成為全球市場推廣的主要催化劑。

圖書館設計流程的專業知識有限

阻礙DNA編碼庫市場發展的關鍵因素是缺乏設計和合成複雜分子庫的專業知識。 DEL需要化學、分子生物學和生物資訊學的高級技術能力和專業知識。許多製藥公司和學術機構在建立內部能力方面面臨挑戰，減緩了其應用速度。雖然外包給專業的合約研究組織（CRO）可以部分彌補這一差距，但依賴外部專業知識往往會增加成本並限制擴充性。因此，有限的設計專業知識限制了DEL平台在全球的快速擴張。

生技企業與製藥公司的合作

生技公司與大型製藥企業建立策略聯盟，為強化DNA編碼化合物庫平台帶來了良好的機會。夥伴關係關係可以共享資源、技術專長和化合物庫，加速新型治療分子的辨識。此類合作促進了跨行業創新，並透過分擔成本降低了開發平臺的風險。越來越多的生物技術企業利用DEL平台，在製藥公司銷售能力的支持下共同開發標靶藥物。這種協作生態系統增強了創新管道，並在治療開發領域開闢了豐厚的利潤機會。

關於使用基因數據的倫理問題

DNA編碼庫市場面臨著與基因資料在研究中使用相關的倫理問題的潛在威脅。雖然DEL專注於藥物研發，但它們通常與基因組資料集交叉，從而引發與隱私和知情同意相關的問題。敏感生物資訊的濫用或未授權存取可能會破壞相關人員之間的信任。此外，各地區嚴格的資料保護條例也為企業帶來了合規挑戰。圍繞基因數據使用的倫理審查仍然是一個重大障礙，可能會阻礙其長期應用。

COVID-19的影響：

COVID-19疫情改變了藥物研發的重點，並加速了DNA編碼庫在快速治療藥物篩檢的應用。 DEL平台實現了針對SARS-CoV-2靶點的高通量化合物篩檢，為抗病毒研究做出了貢獻。然而，供應鏈中斷暫時影響了合成工作流程和實驗室合作。疫情過後，人們重新重視感染疾病的防範，凸顯了可擴展藥物研發方法的重要性。隨著新冠疫情以外的藥物研發管線不斷擴展，DEL平台已成為支援研發速度和效率的關鍵工具。

預測期內，DNA寡核苷酸片段預計將達到最大

DNA寡核苷酸領域預計將在預測期內佔據最大的市場佔有率，這得益於其在構建和編碼海量分子庫中的重要作用。 DNA寡核苷酸如同條碼，能夠大規模辨識結合交互作用。其在高通量篩檢中的多功能性以及在腫瘤學、免疫學和感染疾病研究中日益成長的應用正在推動需求成長。合成技術的不斷進步使DNA寡核苷酸更具成本效益，進一步鞏固了其在市場中的主導地位。

預測期內，文庫設計與合成部分將以最高複合年成長率成長

預計化合物庫設計和合成領域將在預測期內實現最高成長率，這得益於針對特定治療標靶客製化化合物庫的需求不斷成長。先進的計算工具和人工智慧驅動的方法使大型化合物庫的精確設計成為可能。製藥公司正在尋求高品質且多樣化的化合物組合，以改善化合物的識別。合約研究組織 (CRO) 與製藥公司之間合作的不斷擴大，正在加速對複雜化合物庫設計工作流程的投資，使該領域成為市場上成長最快的領域。

佔比最高的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率，這得益於不斷擴大的醫藥研發基地、政府對生物技術的投資增加以及成本效益更高的臨床試驗。中國、印度和日本等國家正積極採用DEL平台來加速藥物研發。強大的產學合作、高水準研究人員的資源以及對平價療法日益成長的需求，正在推動該地區的成長。憑藉規模成長、成本優勢和技術創新的不斷提升，該地區已在DEL市場確立了主導地位。

複合年成長率最高的地區：

預計北美在預測期內將呈現最高的複合年成長率，這得益於其強大的製藥基礎設施、先進的技術應用以及雄厚的研究資金。在大型製藥企業、生技新興企業和學術機構的支持下，美國仍是DEL創新的重要樞紐。與合約研究組織（CRO）的持續合作以及對精準醫療的持續投資進一步支持了成長。強大的監管支持和成熟的醫療保健生態系統使北美成為成長最快的地區，為快速擴張創造了肥沃的土壤。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球DNA編碼圖書館市場（按材質）

  • DNA寡核苷酸
  • 化學連接體
  • 合成塊

6.全球DNA 編碼圖書館市場（依工作流程）

  • 文庫篩檢與分析
  • 圖書館設計與合成

7. 全球DNA編碼圖書館市場（依技術）

  • DNA引導合成（DDS）
  • DNA記錄合成
  • DNA模板合成
  • DNA標記親和性選擇
  • 其他技術

8. 全球DNA編碼圖書館市場（依分銷管道）

  • 直銷（B2B供應）
  • 合約/外包服務
  • 線上平台

9. 全球DNA編碼圖書館市場（按應用）

  • 藥物研發
  • 目標識別和檢驗

10.全球DNA 編碼圖書館市場（依最終用戶分類）

  • 製藥公司
  • 生技公司
  • 合約研究組織

11.全球DNA 編碼圖書館市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章：企業概況

  • X-Chem
  • HitGen
  • Nuevolution（Amgen）
  • Vipergen
  • GSK
  • Merck KGaA
  • WuXi AppTec
  • GenScript
  • Pharmaron
  • Aurigene Pharmaceutical Services
  • BOC Sciences
  • LGC Bioresearch Technologies
  • SPT Labtech Ltd.
  • Life Chemicals
  • Charles River Laboratories
  • DyNAbind
  • ComInnex
Product Code: SMRC30733

According to Stratistics MRC, the Global DNA Encoded Library Market is accounted for $3.5 billion in 2025 and is expected to reach $6.7 billion by 2032 growing at a CAGR of 9.8% during the forecast period. DNA Encoded Libraries are collections of small molecules chemically linked to unique DNA sequences that act as barcodes, enabling rapid identification of compounds with biological activity. Used in drug discovery, they allow high-throughput screening of millions to billions of compounds against target proteins. DNA tags enable efficient selection, amplification, and sequencing of potential drug candidates. This technology combines chemistry and molecular biology, streamlining early-stage pharmaceutical research and significantly accelerating the identification of promising leads.

According to the World Health Organization (WHO), with a growing share being allocated to innovative drug discovery technologies like DECLs. Pharmaceutical companies are seeking to diversify their pipelines and identify novel compounds for unmet medical needs, particularly in cancer, neurological diseases, and rare genetic disorders, where DECLs are particularly promising.

Market Dynamics:

Driver:

Increasing investments in pharmaceutical R&D

The DNA encoded library market is driven by escalating investments in pharmaceutical research and development aimed at accelerating drug discovery. Pharmaceutical companies and research institutes are channeling significant funds into advanced screening technologies to identify novel drug candidates efficiently. DEL platforms enable rapid testing of billions of compounds, reducing cost and time in preclinical phases. Fueled by rising chronic disease prevalence and demand for precision medicine, pharmaceutical R&D expansion continues to be a primary catalyst for market adoption globally.

Restraint:

Limited expertise in library design processes

A major restraint hindering the DNA encoded library market is the shortage of expertise in designing and synthesizing complex molecular libraries. DEL requires advanced technical proficiency and specialized knowledge in chemistry, molecular biology, and bioinformatics. Many pharmaceutical firms and academic institutions face challenges in establishing in-house capabilities, slowing wider adoption. Outsourcing to specialized CROs partly mitigates this gap, but dependency on external expertise often raises costs and limits scalability. Consequently, limited design expertise restricts rapid expansion of DEL platforms globally.

Opportunity:

Collaborations between biotech and pharma companies

A promising opportunity lies in strategic collaborations between biotechnology firms and large pharmaceutical players to enhance DNA encoded library platforms. Partnerships allow pooling of resources, technical expertise, and compound collections, enabling accelerated identification of novel therapeutic molecules. Such alliances foster cross-industry innovation and de-risk R&D pipelines by sharing costs. Increasingly, biotech startups are leveraging DEL platforms to co-develop targeted drugs, supported by pharma's distribution capabilities. This collaborative ecosystem strengthens innovation pipelines and opens lucrative opportunities in therapeutic development.

Threat:

Ethical concerns regarding genetic data usage

The DNA encoded library market faces potential threats from ethical concerns linked to the use of genetic data in research. While DEL focuses on drug discovery, it often intersects with genomic datasets that raise privacy and consent-related issues. Misuse or unauthorized access to sensitive biological information could undermine trust among stakeholders. Additionally, stringent data protection regulations across regions add compliance challenges for companies. Ethical scrutiny around genetic data usage remains a significant barrier that may hinder long-term adoption.

Covid-19 Impact:

The COVID-19 pandemic reshaped priorities in drug discovery, accelerating adoption of DNA encoded libraries for rapid therapeutic screening. DEL platforms enabled high-throughput screening of compounds against SARS-CoV-2 targets, contributing to antiviral research. However, supply chain disruptions temporarily impacted synthesis workflows and laboratory collaborations. Post-pandemic, renewed focus on preparedness against infectious diseases has reinforced the importance of scalable drug discovery methods. As pharmaceutical pipelines broaden beyond COVID-19, DEL platforms are positioned as vital tools supporting speed and efficiency in R&D.

The DNA oligonucleotides segment is expected to be the largest during the forecast period

The DNA oligonucleotides segment is expected to account for the largest market share during the forecast period, propelled by their essential role in constructing and encoding vast molecular libraries. DNA oligos act as barcodes, enabling identification of binding interactions at scale. Their versatility in high-throughput screening and expanding applications across oncology, immunology, and infectious disease research boost demand. With continuous advancements in synthesis techniques, DNA oligonucleotides are becoming more cost-efficient, further strengthening their dominant position in the DEL market landscape.

The library design & synthesis segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the library design & synthesis segment is predicted to witness the highest growth rate, influenced by the increasing demand for customized compound libraries tailored to specific therapeutic targets. Advanced computational tools and AI-driven approaches are enabling precise design of large-scale libraries. Pharmaceutical companies are seeking high-quality, diverse compound sets to improve hit identification. As collaborations between CROs and pharma expand, investment in sophisticated library design workflows is accelerating, making this the fastest-growing segment in the market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, fueled by expanding pharmaceutical R&D hubs, rising government investments in biotechnology, and cost-efficient clinical trials. Countries like China, India, and Japan are actively adopting DEL platforms to accelerate new drug discovery. Strong academic-industry partnerships, availability of skilled researchers, and growing demand for affordable therapeutics strengthen regional growth. The region's ability to combine scale, cost advantages, and increasing innovation drives its leadership position in the DEL market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by strong pharmaceutical infrastructure, advanced technological adoption, and high research funding. The U.S. remains a key hub for DEL innovation, supported by leading pharma giants, biotech startups, and academic institutions. Ongoing collaborations with CROs and rising investment in precision medicine further fuel growth. Robust regulatory support and an established healthcare ecosystem create fertile ground for rapid expansion, positioning North America as the fastest-growing region.

Key players in the market

Some of the key players in DNA Encoded Library Market include X-Chem, HitGen, Nuevolution, Vipergen, GSK, Merck KGaA, WuXi AppTec, GenScript, Pharmaron, Aurigene Discovery Technologies Ltd., BOC Sciences, LGC Bioresearch Technologies, SPT Labtech, Life Chemicals, Charles River Laboratories, DyNAbind GmbH, and Cominmex.

Key Developments:

In August 2025, X-Chem significantly expanded its DNA encoded library platform by introducing a new high-capacity library. This advancement facilitates accelerated drug discovery, enabling researchers to target a wider and more diverse array of protein classes with improved efficiency and precision.

In July 2025, HitGen announced a strategic collaboration with several pharmaceutical partners aimed at leveraging its DNA encoded library technology to identify targets for cancer immunotherapy. This collaboration is expected to enhance the company's capabilities in developing innovative cancer treatments.

In June 2025, Nuevolution launched an enhanced DNA encoded library (DEL) screening platform that integrates advanced AI-driven analytics. This platform improves the accuracy and speed of hit identification, accelerating the drug discovery process by enabling more efficient analysis of large data sets.

Materials Covered:

  • DNA Oligonucleotides
  • Chemical Linkers
  • Synthetic Building Blocks

Workflows Covered:

  • Library Screening & Analysis
  • Library Design & Synthesis

Technologies Covered:

  • DNA-Directed Synthesis (DDS)
  • DNA-Recorded Synthesis
  • DNA-Templated Synthesis
  • DNA-Tagged Affinity Selection
  • Other Technologies

Distribution Channels Covered:

  • Direct Sales (B2B Supply)
  • Contract/Outsourced Services
  • Online Platforms

Applications Covered:

  • Drug Discovery & Development
  • Target Identification & Validation

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Contract Research Organizations

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global DNA Encoded Library Market, By Material

  • 5.1 Introduction
  • 5.2 DNA Oligonucleotides
  • 5.3 Chemical Linkers
  • 5.4 Synthetic Building Blocks

6 Global DNA Encoded Library Market, By Workflow

  • 6.1 Introduction
  • 6.2 Library Screening & Analysis
  • 6.3 Library Design & Synthesis

7 Global DNA Encoded Library Market, By Technology

  • 7.1 Introduction
  • 7.2 DNA-Directed Synthesis (DDS)
  • 7.3 DNA-Recorded Synthesis
  • 7.4 DNA-Templated Synthesis
  • 7.5 DNA-Tagged Affinity Selection
  • 7.6 Other Technologies

8 Global DNA Encoded Library Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Direct Sales (B2B Supply)
  • 8.3 Contract/Outsourced Services
  • 8.4 Online Platforms

9 Global DNA Encoded Library Market, By Application

  • 9.1 Introduction
  • 9.2 Drug Discovery & Development
  • 9.3 Target Identification & Validation

10 Global DNA Encoded Library Market, By End User

  • 10.1 Introduction
  • 10.2 Pharmaceutical Companies
  • 10.3 Biotechnology Firms
  • 10.4 Contract Research Organizations

11 Global DNA Encoded Library Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 X-Chem
  • 13.2 HitGen
  • 13.3 Nuevolution (Amgen)
  • 13.4 Vipergen
  • 13.5 GSK
  • 13.6 Merck KGaA
  • 13.7 WuXi AppTec
  • 13.8 GenScript
  • 13.9 Pharmaron
  • 13.10 Aurigene Pharmaceutical Services
  • 13.11 BOC Sciences
  • 13.12 LGC Bioresearch Technologies
  • 13.13 SPT Labtech Ltd.
  • 13.14 Life Chemicals
  • 13.15 Charles River Laboratories
  • 13.16 DyNAbind
  • 13.17 ComInnex

List of Tables

  • Table 1 Global DNA Encoded Library Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global DNA Encoded Library Market Outlook, By Material (2024-2032) ($MN)
  • Table 3 Global DNA Encoded Library Market Outlook, By DNA Oligonucleotides (2024-2032) ($MN)
  • Table 4 Global DNA Encoded Library Market Outlook, By Chemical Linkers (2024-2032) ($MN)
  • Table 5 Global DNA Encoded Library Market Outlook, By Synthetic Building Blocks (2024-2032) ($MN)
  • Table 6 Global DNA Encoded Library Market Outlook, By Workflow (2024-2032) ($MN)
  • Table 7 Global DNA Encoded Library Market Outlook, By Library Screening & Analysis (2024-2032) ($MN)
  • Table 8 Global DNA Encoded Library Market Outlook, By Library Design & Synthesis (2024-2032) ($MN)
  • Table 9 Global DNA Encoded Library Market Outlook, By Technology (2024-2032) ($MN)
  • Table 10 Global DNA Encoded Library Market Outlook, By DNA-Directed Synthesis (DDS) (2024-2032) ($MN)
  • Table 11 Global DNA Encoded Library Market Outlook, By DNA-Recorded Synthesis (2024-2032) ($MN)
  • Table 12 Global DNA Encoded Library Market Outlook, By DNA-Templated Synthesis (2024-2032) ($MN)
  • Table 13 Global DNA Encoded Library Market Outlook, By DNA-Tagged Affinity Selection (2024-2032) ($MN)
  • Table 14 Global DNA Encoded Library Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 15 Global DNA Encoded Library Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 16 Global DNA Encoded Library Market Outlook, By Direct Sales (B2B Supply) (2024-2032) ($MN)
  • Table 17 Global DNA Encoded Library Market Outlook, By Contract/Outsourced Services (2024-2032) ($MN)
  • Table 18 Global DNA Encoded Library Market Outlook, By Online Platforms (2024-2032) ($MN)
  • Table 19 Global DNA Encoded Library Market Outlook, By Application (2024-2032) ($MN)
  • Table 20 Global DNA Encoded Library Market Outlook, By Drug Discovery & Development (2024-2032) ($MN)
  • Table 21 Global DNA Encoded Library Market Outlook, By Target Identification & Validation (2024-2032) ($MN)
  • Table 22 Global DNA Encoded Library Market Outlook, By End User (2024-2032) ($MN)
  • Table 23 Global DNA Encoded Library Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 24 Global DNA Encoded Library Market Outlook, By Biotechnology Firms (2024-2032) ($MN)
  • Table 25 Global DNA Encoded Library Market Outlook, By Contract Research Organizations (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.